To the Editor: Lately, arsenic trioxide (As2O3 ) has been described in the treatment of acute myeloid leukemia. Experiments in vitro showed that As2O3 induced the acute promyelocytic leukemia (APL) cell line NB4 to downregulate bcl-2 expression, as well as to undergo apoptosis.[1][1] Clinically
No takes yet. Share an insight, caveat, or question.
Kwong et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: